Compare SEER & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEER | GNLX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.0M | 110.4M |
| IPO Year | 2020 | 2022 |
| Metric | SEER | GNLX |
|---|---|---|
| Price | $1.95 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 188.3K | ★ 297.3K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.40 | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,578,000.00 | $8,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $25.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.55 | $2.29 |
| 52 Week High | $2.41 | $8.54 |
| Indicator | SEER | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 42.93 |
| Support Level | $1.83 | $2.51 |
| Resistance Level | $1.99 | $2.95 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.55 | 28.57 |
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.